For prodromal AD vs controls, the cutoffs were CSF t-tau >504 ng/L (sensitivity 86%, specificity 70%), CSF p-tau >73 ng/L (sensitivity 79%, specificity 93%), 18F-AV-1451 tau stage I–IV >1.41 SUVR (sensitivity 79%, specificity 87%), and 18F-AV-1451 tau stage I–V >1.43 SUVR (sensitivity 57%, specificity 100%). The gene discussed is MAPT; the disease is Alzheimer disease.